People also watch:NVSGSKAZNLLYNVO
42.310.41 (0.98%)

After hours: 42.15-0.16 (-0.38%) as of 5:16 PM EDT

Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close41.90
Bid42.28 x 1900
Ask42.29 x 600
52wk Range37.41 - 54.98
Day's Range41.98 - 42.45
Avg Vol (3m)2,321,230
As of 4:02 PM EDT. Market closed.
  • Eli Lilly, J&J, Novo Battle Diabetes -- And Each Other
    Investor's Business Daily14 hours ago

    Eli Lilly, J&J, Novo Battle Diabetes -- And Each Other

    Potential blockbuster combo drugs from Sanofi and Novo Nordisk are near launch, and reducing death rates may be next battleground.

  • Forbes18 hours ago

    Six Major Biotech Acquisitions You Could See in 2016 (Part 2)

    Is this the best time in a long time to be buying biotech stocks now that their lagging performance has made them relatively undervalued to other sectors? Todd Hagopian is buying because he believes the biotech industry is ripe for acquisitions as large, cash-flow rich drug companies look for promising new products. This is the 2nd in a three-part series focusing on potential mergers and acquisitions in the biotech sector.